IQVIA management check
IQV · Health Care · Life Sciences Tools & Services · CEO Ari Bousbib
Filings as of
4 good · 2 to watch · 1 flagged, across the seven questions below.
- Flag
Have owners done well?
Trailed its chosen peers$100 invested at the start of fiscal 2021 grew to $126, against $187 for the peer group the company picked itself.
- Good
Does pay follow performance?
Pay rose and fell with returnsOver 5 years, the CEO's pay actually paid (equity valued at the share price) had a correlation of 0.99 with shareholder return. 1 means pay moved in step; below 0, the opposite way.
- Watch
What does the CEO cost owners?
2.1% of net income$28.1m of reported pay in fiscal 2025, against $1.4bn of net income.
- Watch
Do they own the stock?
Insiders are selling6 insiders sold $29.9m in the last six months and none bought.
- Good
Are owners being diluted?
Share count shrinkingDiluted shares changed -3.5% a year over the last three fiscal years. Stock-based pay was 1.5% of revenue in the latest year.
- Good
Is leadership stable?
4 leadership filings in 3 yearsCEO in the pay table: Ari Bousbib. 4 filings under 8-K item 5.02 (officers or directors leaving or joining, or new pay arrangements) in the last 3 years.
- Good
Are the books clean?
No red flags on fileNo restatements, auditor changes or late filings since 2021.
Against the S&P 500
Each check's score (0–100) and how it compares: the share of ranked S&P 500 companies it matches or beats, and the median in Health Care.
| Check | Score | At or above | Sector median |
|---|---|---|---|
| Owner returns | 9 | 26 | |
| Pay for performance | 99 | 85 | |
| CEO cost | 24 | 44 | |
| Skin in the game | — | — | 46 |
| Dilution | 94 | 68 | |
| Stable leadership | 100 | 70 | |
| Clean books | 100 | 100 |
Closest peers
Others in Life Sciences Tools & Services, by management score. IQVIA is 17th of 60 in its sector.
- 104WATWaters Corporation76
- 173IQVIQVIA71
- 218MTDMettler Toledo67
- 297DHRDanaher Corporation62
- 301TMOThermo Fisher Scientific61
- 374CRLCharles River Laboratories56
- 397AAgilent Technologies53
- 422TECHBio-Techne50
- 444ILMNIllumina, Inc.47
Pay versus performance
From the proxy statement filed February 27, 2026. "Actually paid" values stock awards at the share price, so it rises and falls with the stock.
| Fiscal year | CEO | CEO pay | Actually paid | Other executives (avg) | $100 became | Peers | Net income |
|---|---|---|---|---|---|---|---|
| 2025 | Ari Bousbib | $28.1m | $36.1m | $8.9m | $126 | $187 | $1.4bn |
| 2024 | — | $26.7m | $11.5m | $6.6m | $110 | $159 | $1.4bn |
| 2023 | — | $29.2m | $42.3m | $4.5m | $129 | $148 | $1.4bn |
| 2022 | — | $30.1m | $6.0m | $5.0m | $114 | $138 | $1.1bn |
| 2021 | — | $28.6m | $88.4m | $4.4m | $157 | $136 | $966.0m |
The board says pay is tied most to Adjusted Diluted EPS Growth. Its other key measures: Adjusted Diluted EPS Growth (as defined in “Compensation Discussion and Analysis—Elements of Compensation—Short-Term Incentive Awards,” described on page 57), Relative Total Stockholder Return (as defined in “Compensation Discussion and Analysis—Elements of Compensation— Long-Term Incentive Awards,” described on page 60), Revenue (as defined in “Compensation Discussion and Analysis—Elements of Compensation—Short-Term Incentive Awards,” described on page 57), Adjusted EBITDA (as defined in “Compensation Discussion and Analysis—Elements of Compensation—Short-Term Incentive Awards,” described on page 57).
Insiders and the CEO's stake
6 insiders sold $29.9m in the last six months and none bought.
- SoldAri BousbibSee Remarks$26.1mJul 29, 2026
- SoldW Richard StaubSee Remarks$1.3mAug 3, 2026
- SoldEric SherbetSee Remarks$1.2mJul 29, 2026
- SoldJames G. BerkshireSee Remarks$697kSep 2, 2026
Leadership and governance on file
- Apr 23, 2026Leadership change8-K 5.02
- Nov 5, 2025Leadership change8-K 5.02
- Sep 2, 2025Leadership change8-K 5.02
- May 10, 2024Leadership change8-K 5.02
- Sep 26, 2023Leadership change8-K 5.02
- Oct 3, 2022Leadership change8-K 5.02
- Jul 29, 2022Leadership change8-K 5.02
- Mar 14, 2022Leadership change8-K 5.02
- Jan 27, 2022Leadership change8-K 5.02
Latest shareholder vote results: Apr 23, 2026, including the say-on-pay vote.
Where the money went
Over 2021–2025: $5.2bn returned to owners in buybacks and dividends, 84% of net income, and $1.0bn of pay in stock.
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $13.9bn | $14.4bn | $15.0bn | $15.4bn | $16.3bn |
| Net income | $966.0m | $1.1bn | $1.4bn | $1.4bn | $1.4bn |
| Stock-based pay | $170.0m | $194.0m | $217.0m | $206.0m | $247.0m |
| Buybacks | $406.0m | $1.2bn | $992.0m | $1.4bn | $1.2bn |
| Dividends | — | — | — | — | — |
| Diluted shares | 195m | 191m | 186m | 183m | 174m |
Educational only, not investment advice. Figures are as filed with the SEC: pay from the proxy's pay-versus-performance table, capital allocation from 10-K XBRL data, insider trades from Form 4s over the last six months, events from the last 5 years of filings. The peer group is the one the company chose. See the method.